Please enable JavaScript to continue using this application.

Compare $INBX vs $REPL | Chartloom

Compare

$INBX vs $REPL

Inhibrx Biosciences Inc · Replimune Group Inc

INBX

Inhibrx Biosciences Inc

REPL

Replimune Group Inc

Compare $INBX vs $REPL

Comparing Inhibrx Biosciences Inc and Replimune Group Inc

INBXInhibrx Biosciences Inc

REPLReplimune Group Inc

INBXInhibrx Biosciences Inc

Market cap

$1.39B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

26.6%

52W performance

182.7%

FCF yield

-9.5%

REPLReplimune Group Inc

Market cap

$1.13B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

40.24x

Rev growth (TTM)

—

YTD performance

50.8%

52W performance

188.6%

FCF yield

-24.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INBX

REPL

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

REPL

Replimune Group Inc

Market Cap

INBX$1.39B

REPL$1.13B

Enterprise Value

INBX$1.44B

REPL$1.05B

Price

INBX$95.01

REPL$13.42

P/E Ratio

INBXN/A

REPLN/A

P/S Ratio

INBX1,019.62x

REPL0.00x

EV/Sales

INBX1,050.29x

REPL0.00x

EV/EBITDA

INBX0.85x

REPL0.00x

P/B Ratio

INBX178.59x

REPL11.66x

P/FCF Ratio

INBXN/A

REPLN/A

EV/FCF

INBX-10.89x

REPL-3.75x

PEG Ratio

INBXN/A

REPLN/A

Forward P/E (NTM)

INBXN/A

REPLN/A

Forward P/S (NTM)

INBXN/A

REPL40.24x

Revenue (TTM)

INBX$0

REPL$0

Revenue Growth (YoY)

INBX-100.0%

REPLN/A

Forward Rev Growth

INBX282.8%

REPL397.3%

Gross Margin (TTM)

INBX0.0%

REPL0.0%

Operating Margin (TTM)

INBX0.0%

REPL0.0%

EBITDA Margin (TTM)

INBX0.0%

REPL0.0%

Net Margin (TTM)

INBX0.0%

REPL0.0%

FCF Margin (TTM)

INBXN/A

REPLN/A

Net Income (TTM)

INBX$-138M

REPL$-297M

FCF (TTM)

INBX$-132M

REPL$-281M

EPS (TTM)

INBX-$8.82

REPL-$3.07

ROE (TTM)

INBX-26956.0%

REPL-15932.0%

ROA (TTM)

INBX-8348.0%

REPL-9084.0%

ROIC (TTM)

INBX-9241.0%

REPL-10727.0%

Cash

INBX$133M

REPL$185M

Debt

INBX$176M

REPL$109M

Net Cash/Debt

INBX$-43M

REPL$77M

Current Ratio (TTM)

INBX5.07x

REPL5.23x

Quick Ratio (TTM)

INBX4.76x

REPL5.09x

Debt/Equity (TTM)

INBX12.58x

REPL1.03x

Debt/Assets (TTM)

INBX0.0%

REPL0.0%

Interest Coverage (TTM)

INBXN/A

REPLN/A

Net Debt/EBITDA (TTM)

INBX0.00x

REPL0.00x

Beta

INBX3.17

REPL0.97

52W Performance

INBX182.7%

REPL188.6%

YTD Performance

INBX26.6%

REPL50.8%

% from 52W High

INBX-38.8%

REPL-17.8%

% from 52W Low

INBX237.4%

REPL794.7%

Asset Turnover (TTM)

INBX0.01x

REPL0.00x

FCF Yield (TTM)

INBX-9.5%

REPL-24.9%

Earnings Yield (TTM)

INBX-9.9%

REPL-26.3%

Dividend Yield (TTM)

INBXN/A

REPLN/A

Rule of 40

INBX-100.0

REPL0.0

EV/GP/RG

INBXN/A

REPLN/A

Ticker research

View INBX research View REPL research

Metric	INBX Inhibrx Biosciences Inc	REPL Replimune Group Inc
Market & Valuation
Market Cap	$1.39B	$1.13B
Enterprise Value	$1.44B	$1.05B
Price	$95.01	$13.42
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	0.00x
EV/Sales	1,050.29x	0.00x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	11.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	40.24x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	282.8%	397.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-138M	$-297M
FCF (TTM)	$-132M	$-281M
EPS (TTM)	-$8.82	-$3.07
ROE (TTM)	-26956.0%	-15932.0%
ROA (TTM)	-8348.0%	-9084.0%
ROIC (TTM)	-9241.0%	-10727.0%
Financial Health
Cash	$133M	$185M
Debt	$176M	$109M
Net Cash/Debt	$-43M	$77M
Current Ratio (TTM)	5.07x	5.23x
Quick Ratio (TTM)	4.76x	5.09x
Debt/Equity (TTM)	12.58x	1.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	0.97
52W Performance	182.7%	188.6%
YTD Performance	26.6%	50.8%
% from 52W High	-38.8%	-17.8%
% from 52W Low	237.4%	794.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-9.5%	-24.9%
Earnings Yield (TTM)	-9.9%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View REPL research

Valuation

P/S Ratio

REPL

0.00x

INBX

1,019.62x

EV/FCF

INBX

-10.89x

REPL

-3.75x

Growth & revenue

Revenue Growth TTM

INBX

-100.0%

Forward Revenue Growth

REPL

397.3%

INBX

282.8%

Profitability & performance

Gross Margin

INBX

0.0%

REPL

0.0%

ROE

REPL

-15932.0%

INBX

-26956.0%

FCF Yield %

INBX

-9.5%

REPL

-24.9%

52-Week Performance

REPL

188.6%

INBX

182.7%

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

REPL

Replimune Group Inc

Market Cap

INBX$1.39B

REPL$1.13B

Enterprise Value

INBX$1.44B

REPL$1.05B

Price

INBX$95.01

REPL$13.42

P/E Ratio

INBXN/A

REPLN/A

P/S Ratio

INBX1,019.62x

REPL0.00x

EV/Sales

INBX1,050.29x

REPL0.00x

EV/EBITDA

INBX0.85x

REPL0.00x

P/B Ratio

INBX178.59x

REPL11.66x

P/FCF Ratio

INBXN/A

REPLN/A

EV/FCF

INBX-10.89x

REPL-3.75x

PEG Ratio

INBXN/A

REPLN/A

Forward P/E (NTM)

INBXN/A

REPLN/A

Forward P/S (NTM)

INBXN/A

REPL40.24x

Revenue (TTM)

INBX$0

REPL$0

Revenue Growth (YoY)

INBX-100.0%

REPLN/A

Forward Rev Growth

INBX282.8%

REPL397.3%

Gross Margin (TTM)

INBX0.0%

REPL0.0%

Operating Margin (TTM)

INBX0.0%

REPL0.0%

EBITDA Margin (TTM)

INBX0.0%

REPL0.0%

Net Margin (TTM)

INBX0.0%

REPL0.0%

FCF Margin (TTM)

INBXN/A

REPLN/A

Net Income (TTM)

INBX$-138M

REPL$-297M

FCF (TTM)

INBX$-132M

REPL$-281M

EPS (TTM)

INBX-$8.82

REPL-$3.07

ROE (TTM)

INBX-26956.0%

REPL-15932.0%

ROA (TTM)

INBX-8348.0%

REPL-9084.0%

ROIC (TTM)

INBX-9241.0%

REPL-10727.0%

Cash

INBX$133M

REPL$185M

Debt

INBX$176M

REPL$109M

Net Cash/Debt

INBX$-43M

REPL$77M

Current Ratio (TTM)

INBX5.07x

REPL5.23x

Quick Ratio (TTM)

INBX4.76x

REPL5.09x

Debt/Equity (TTM)

INBX12.58x

REPL1.03x

Debt/Assets (TTM)

INBX0.0%

REPL0.0%

Interest Coverage (TTM)

INBXN/A

REPLN/A

Net Debt/EBITDA (TTM)

INBX0.00x

REPL0.00x

Beta

INBX3.17

REPL0.97

52W Performance

INBX182.7%

REPL188.6%

YTD Performance

INBX26.6%

REPL50.8%

% from 52W High

INBX-38.8%

REPL-17.8%

% from 52W Low

INBX237.4%

REPL794.7%

Asset Turnover (TTM)

INBX0.01x

REPL0.00x

FCF Yield (TTM)

INBX-9.5%

REPL-24.9%

Earnings Yield (TTM)

INBX-9.9%

REPL-26.3%

Dividend Yield (TTM)

INBXN/A

REPLN/A

Rule of 40

INBX-100.0

REPL0.0

EV/GP/RG

INBXN/A

REPLN/A

Ticker research

View INBX research View REPL research

Metric	INBX Inhibrx Biosciences Inc	REPL Replimune Group Inc
Market & Valuation
Market Cap	$1.39B	$1.13B
Enterprise Value	$1.44B	$1.05B
Price	$95.01	$13.42
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	0.00x
EV/Sales	1,050.29x	0.00x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	11.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	40.24x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	282.8%	397.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-138M	$-297M
FCF (TTM)	$-132M	$-281M
EPS (TTM)	-$8.82	-$3.07
ROE (TTM)	-26956.0%	-15932.0%
ROA (TTM)	-8348.0%	-9084.0%
ROIC (TTM)	-9241.0%	-10727.0%
Financial Health
Cash	$133M	$185M
Debt	$176M	$109M
Net Cash/Debt	$-43M	$77M
Current Ratio (TTM)	5.07x	5.23x
Quick Ratio (TTM)	4.76x	5.09x
Debt/Equity (TTM)	12.58x	1.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	0.97
52W Performance	182.7%	188.6%
YTD Performance	26.6%	50.8%
% from 52W High	-38.8%	-17.8%
% from 52W Low	237.4%	794.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-9.5%	-24.9%
Earnings Yield (TTM)	-9.9%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View REPL research